Genetically engineered human islets protected from CD8-mediated autoimmune destruction in vivo

Area of Science:

• Immunology
• Endocrinology
• Cell Biology

Background:

• Type 1 diabetes is an autoimmune disease targeting insulin-producing beta cells.
• Islet transplantation is a potential therapy but faces challenges from recurrent autoimmunity.
• Protecting transplanted islets from immune attack is crucial for long-term graft survival.

Purpose of the Study:

• To engineer human beta cells to resist autoimmune destruction using viral immune-evasion proteins (immunevasins).
• To evaluate the efficacy of these engineered beta cells in vitro and in vivo models.
• To demonstrate functional preservation of genetically modified beta cells.

Main Methods:

• Human beta cells were genetically modified using lentiviral vectors to express herpesvirus immune-evasion proteins.
• A beta-cell-specific reporter gene assay was developed to assess T-cell-mediated killing.
• In vitro and in vivo studies (humanized mice) were conducted to evaluate protection and function.

Main Results:

• Engineered human beta cells expressing US2 (human cytomegalovirus) and serpin B9 demonstrated significant protection against autoreactive T-cell killing in vitro.
• Coimplantation of modified beta cells with T cells in immunodeficient mice preserved insulin production and C-peptide secretion.
• Genetic modification did not impair the function of primary human beta cells.

Conclusions:

• Human beta cells can be effectively engineered for immune protection against autoimmune T-cell-mediated killing.
• This approach offers a proof of concept for enhancing islet graft survival in type 1 diabetes.
• The study highlights the potential of immunevasins for improving islet transplantation outcomes.